GlassScriptPhysician profile
Lauren Carrasco
NPI 1609384965
$8,408.54
in general payments reported to CMS, 2019-2025
49 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $1,354 · 2023: $1,858 · 2024: $1,957 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,696 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,695.89 |
| Education | $149.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,387.82 | 2021-2025 | |
| Novo Nordisk INC | $792.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $699.83 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $578.02 | 2022-2025 | Veozah |
| Pfizer INC. | $536.38 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.27 | 2021-2025 | Jardiance |
| Antares Pharma, INC. | $429.13 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $383.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $368.25 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $246.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $241.07 | 2021-2025 | |
| Amgen INC. | $231.11 | 2021-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $201.95 | 2021-2022 | |
| Dexcom, INC. | $152.00 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $141.45 | 2021-2025 | Freestyle Libre 3 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Carrasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.